Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Down 11.3% in November

Basilea Pharmaceutica AG (OTCMKTS:BPMUFGet Free Report) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 26,700 shares, a decrease of 11.3% from the October 31st total of 30,100 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Basilea Pharmaceutica Stock Performance

Shares of OTCMKTS BPMUF remained flat at $52.83 during midday trading on Friday. The stock’s 50-day moving average price is $52.39 and its two-hundred day moving average price is $49.90. Basilea Pharmaceutica has a 12 month low of $38.60 and a 12 month high of $52.83.

Analysts Set New Price Targets

Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.

Check Out Our Latest Research Report on BPMUF

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

See Also

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.